Clinical Trial Update: APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating APF530 or Aloxi (palonosetron hydrochloride) in combination with dexamethasone to prevent chemotherapy-induced nausea and vomiting in a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• APF530 (granisetron extended-release formulation)
• Aloxi (palonosetron hydrochloride)
• DEXAMETHASONE (Dexamethasone)

Snippet

Sponsor: Heron Therapeutics | Conditions: Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific | Phase 3 | Status: COMPLETED | Results posted: 2016-12-28